Using pasireotide to treat advanced synovial sarcoma and desmoplastic small round cell tumor
Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
This study is testing if the drug pasireotide can help young people with advanced synovial sarcoma and desmoplastic small round cell tumors stay healthy longer after their initial treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 13 Years to 50 Years |
| Sex | All |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 4 sites (Heidelberg, Baden-Wurttemberg and 3 other locations) |
| Trial ID | NCT06456359 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy of pasireotide, a somatostatin analog, as a maintenance treatment for patients with advanced desmoplastic small round cell tumor (DSRCT) and synovial sarcoma (SySa). The study focuses on patients aged 13 to 50 years who have shown stable disease or response after standard treatments and have high expression of specific somatostatin receptors. Participants will receive pasireotide via intragluteal injection every 28 days, and the trial aims to assess progression-free survival and overall survival rates. The study will also analyze measurable residual disease before, during, and after treatment.
Who should consider this trial
Good fit: Ideal candidates are adolescents and young adults aged 13 to 50 with advanced DSRCT or SySa who have high somatostatin receptor expression and have not responded to curative treatments.
Not a fit: Patients with curative treatment options or those outside the age range of 13 to 50 years may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve survival outcomes for patients with advanced DSRCT and SySa.
How similar studies have performed: While the use of somatostatin analogs in cancer treatment has shown promise, this specific application in DSRCT and SySa is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
Patients meeting all of the following criteria are considered for enrolment into the trial:
1. Reference pathological proven diagnosis of DSRCT in any stage; or Reference pathological proven diagnosis of SySa, IRS III, metastatic or relapsed disease
2. High SSTR2/3/5 mRNA expression, as determined by RNA sequencing in the DKFZ/NCT/DKTK MASTER (ClinicalTrials.gov ID: NCT05852522) or INFORM programs.
3. Stable disease, partial or complete response after completion of standard treatment
4. Age from 13 to 50 years
5. For patients (≥16 years): Karnofsky-Index ≥ 80% For patients (\<16 years): Lansky-Index ≥ 80%
6. No curative treatment option
7. Bodyweight ≥ 30kg and BSA ≥ 1.1m²
8. Time from last chemotherapy (at least 2 chemotherapy cycles) to enrollment \<8 weeks
9. Ability of patient to understand character and individual consequences of the clinical trial
10. Written informed consent (for individuals \<18 years of age an ICF for adolescents and their parents is needed)
11. For women of childbearing potential negative urine pregnancy test at screening as well as highly effective forms of contraception have to be in place thereafter
* Evidence of childbearing potential is defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile
* Postmenopausal or evidence of non-childbearing status is defined as:
* Amenorrhea for 1 year or more without an alternative medical cause following cessation of exogenous hormonal treatments plus follicle stimulating hormone (FSH) levels in the postmenopausal range in women not using hormonal contraception or hormonal replacement therapy.
* Chemotherapy-induced menopause
* Surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, total hysterectomy or tubal ligation at least 6 weeks before IMP treatment)
* A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy
12. Female patients of childbearing potential and male patients with partners of childbearing potential who are sexually active must agree to the use of two forms of contraception in combination (male condom and one highly effective method). These should be started immediately after signing the informed consent form and continued throughout the period of study treatment plus 3 months for female and male patients . Male patients should refrain from fathering a child or donating sperm during the trial and for at least 3 months following the last dose.
13. Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:
* Hemoglobin ≥ 10 g/dl
* Neutrophil count ≥ 1,500/mm3
* Platelet count ≥ 100,000/µl
* Bilirubin ≤ 1.5 x upper limit of normal (ULN)
* ALT and AST ≤ 2.5 x ULN
* Alkaline phosphatase ≤ 2.5 x ULN
* PT-INR/PTT ≤ 1.5 x ULN
* Albumin ≥ 25 g/l
* Creatine kinase ≤ 2.5 x ULN
* Serum creatinine \< or = 1.5 mg/dl or creatinine clearance = or \> 51 ml/min (calculation according to Crockroft-Gault)
Exclusion Criteria:
Patients presenting with any of the following criteria are not included in the trial:
1. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
2. Concurrent or previous treatment within 30 days in another interventional clinical trial / Participation in other ongoing clinical trials.
3. Uncontrolled concurrent disease, in particular diabetes mellitus
4. Bleeding disorder
5. Therapeutic anticoagulation which cannot be paused temporarily in order to ensure safe intramuscular injection
6. Is taking or requiring any of the prohibited medication listed in Table 5 (6.4.2)
7. Heart rate at rest \< 60/min
8. fasting glucose level \> 110mg/dl
9. Severe neurologic or psychiatric disorder
10. Pregnancy/lactation
11. Prior treatment with somatostatin analog
\-
Where this trial is running
Heidelberg, Baden-Wurttemberg and 3 other locations
- National Center for Tumour Diseases, University Hospital Heidelberg — Heidelberg, Baden-Wurttemberg, Germany (Recruiting)
- Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin — Stuttgart, Baden-Wurttemberg, Germany (Not_yet_recruiting)
- Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl — Stuttgart, Baden-Wurttemberg, Germany (Not_yet_recruiting)
- Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie — Essen, North Rhine-Westphalia, Germany (Not_yet_recruiting)
Study contacts
- Principal investigator: Richard F. Schlenk, Professor — National Center for Tumour Diseases, University Hospital Heidelberg
- Study coordinator: Richard F. Schlenk, Professor
- Email: richard.schlenk@nct-heidelberg.de
- Phone: +49 (0)6221 56 6228
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.